vs

Side-by-side financial comparison of IDACORP INC (IDA) and Orthofix Medical Inc. (OFIX). Click either name above to swap in a different company.

IDACORP INC is the larger business by last-quarter revenue ($360.1M vs $219.9M, roughly 1.6× Orthofix Medical Inc.). IDACORP INC runs the higher net margin — 12.1% vs -1.0%, a 13.1% gap on every dollar of revenue. On growth, Orthofix Medical Inc. posted the faster year-over-year revenue change (2.0% vs -4.2%). Orthofix Medical Inc. produced more free cash flow last quarter ($16.8M vs $-216.2M). Over the past eight quarters, Orthofix Medical Inc.'s revenue compounded faster (8.0% CAGR vs -7.2%).

IDACORP, Inc is an electricity holding company, incorporated in Idaho with headquarters in Boise. It comprises Idaho Power Company, IDACORP Financial and Ida-West Energy. It was formed on October 1, 1998.

Orthofix Medical Inc. is a global medical device firm specializing in orthopedic care. It develops, manufactures and sells spinal implants, trauma care products, bone growth stimulation therapies and regenerative medicine offerings, serving orthopedic surgeons and healthcare providers across North America, Europe and Asia Pacific.

IDA vs OFIX — Head-to-Head

Bigger by revenue
IDA
IDA
1.6× larger
IDA
$360.1M
$219.9M
OFIX
Growing faster (revenue YoY)
OFIX
OFIX
+6.2% gap
OFIX
2.0%
-4.2%
IDA
Higher net margin
IDA
IDA
13.1% more per $
IDA
12.1%
-1.0%
OFIX
More free cash flow
OFIX
OFIX
$233.0M more FCF
OFIX
$16.8M
$-216.2M
IDA
Faster 2-yr revenue CAGR
OFIX
OFIX
Annualised
OFIX
8.0%
-7.2%
IDA

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
IDA
IDA
OFIX
OFIX
Revenue
$360.1M
$219.9M
Net Profit
$43.6M
$-2.2M
Gross Margin
71.1%
Operating Margin
14.9%
0.2%
Net Margin
12.1%
-1.0%
Revenue YoY
-4.2%
2.0%
Net Profit YoY
15.1%
92.4%
EPS (diluted)
$0.78
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
IDA
IDA
OFIX
OFIX
Q4 25
$360.1M
$219.9M
Q3 25
$526.4M
$205.6M
Q2 25
$449.3M
$203.1M
Q1 25
$411.1M
$193.6M
Q4 24
$375.9M
$215.7M
Q3 24
$532.5M
$196.6M
Q2 24
$442.6M
$198.6M
Q1 24
$417.9M
$188.6M
Net Profit
IDA
IDA
OFIX
OFIX
Q4 25
$43.6M
$-2.2M
Q3 25
$124.4M
$-22.8M
Q2 25
$95.8M
$-14.1M
Q1 25
$59.6M
$-53.1M
Q4 24
$37.9M
$-29.1M
Q3 24
$113.6M
$-27.4M
Q2 24
$89.5M
$-33.4M
Q1 24
$48.2M
$-36.0M
Gross Margin
IDA
IDA
OFIX
OFIX
Q4 25
71.1%
Q3 25
72.2%
Q2 25
68.7%
Q1 25
62.8%
Q4 24
69.0%
Q3 24
68.7%
Q2 24
67.8%
Q1 24
67.5%
Operating Margin
IDA
IDA
OFIX
OFIX
Q4 25
14.9%
0.2%
Q3 25
27.5%
-8.3%
Q2 25
22.4%
-7.9%
Q1 25
13.4%
-25.2%
Q4 24
11.0%
-5.3%
Q3 24
25.1%
-9.6%
Q2 24
23.3%
-12.5%
Q1 24
11.9%
-15.6%
Net Margin
IDA
IDA
OFIX
OFIX
Q4 25
12.1%
-1.0%
Q3 25
23.6%
-11.1%
Q2 25
21.3%
-6.9%
Q1 25
14.5%
-27.4%
Q4 24
10.1%
-13.5%
Q3 24
21.3%
-13.9%
Q2 24
20.2%
-16.8%
Q1 24
11.5%
-19.1%
EPS (diluted)
IDA
IDA
OFIX
OFIX
Q4 25
$0.78
$-0.05
Q3 25
$2.26
$-0.57
Q2 25
$1.76
$-0.36
Q1 25
$1.10
$-1.35
Q4 24
$0.72
$-0.76
Q3 24
$2.12
$-0.71
Q2 24
$1.71
$-0.88
Q1 24
$0.95
$-0.95

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
IDA
IDA
OFIX
OFIX
Cash + ST InvestmentsLiquidity on hand
$215.7M
$82.0M
Total DebtLower is stronger
$3.3B
Stockholders' EquityBook value
$3.6B
$450.0M
Total Assets
$10.2B
$850.6M
Debt / EquityLower = less leverage
0.93×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
IDA
IDA
OFIX
OFIX
Q4 25
$215.7M
$82.0M
Q3 25
$333.2M
$62.9M
Q2 25
$474.5M
$65.6M
Q1 25
$634.5M
$58.0M
Q4 24
$368.9M
$83.2M
Q3 24
$427.9M
$30.1M
Q2 24
$169.6M
$26.4M
Q1 24
$157.6M
$27.0M
Total Debt
IDA
IDA
OFIX
OFIX
Q4 25
$3.3B
Q3 25
$157.2M
Q2 25
$157.0M
Q1 25
$156.9M
Q4 24
$3.1B
$157.0M
Q3 24
$118.5M
Q2 24
$118.0M
Q1 24
$118.2M
Stockholders' Equity
IDA
IDA
OFIX
OFIX
Q4 25
$3.6B
$450.0M
Q3 25
$3.5B
$442.5M
Q2 25
$3.4B
$458.3M
Q1 25
$3.3B
$458.3M
Q4 24
$3.3B
$503.1M
Q3 24
$3.3B
$525.9M
Q2 24
$3.2B
$546.0M
Q1 24
$2.9B
$570.3M
Total Assets
IDA
IDA
OFIX
OFIX
Q4 25
$10.2B
$850.6M
Q3 25
$10.1B
$832.6M
Q2 25
$9.9B
$837.2M
Q1 25
$9.6B
$823.1M
Q4 24
$9.2B
$893.3M
Q3 24
$9.1B
$867.9M
Q2 24
$8.7B
$882.0M
Q1 24
$8.3B
$906.0M
Debt / Equity
IDA
IDA
OFIX
OFIX
Q4 25
0.93×
Q3 25
0.36×
Q2 25
0.34×
Q1 25
0.34×
Q4 24
0.92×
0.31×
Q3 24
0.23×
Q2 24
0.22×
Q1 24
0.21×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
IDA
IDA
OFIX
OFIX
Operating Cash FlowLast quarter
$137.8M
$27.7M
Free Cash FlowOCF − Capex
$-216.2M
$16.8M
FCF MarginFCF / Revenue
-60.0%
7.6%
Capex IntensityCapex / Revenue
98.3%
4.9%
Cash ConversionOCF / Net Profit
3.16×
TTM Free Cash FlowTrailing 4 quarters
$-577.5M
$-1.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
IDA
IDA
OFIX
OFIX
Q4 25
$137.8M
$27.7M
Q3 25
$162.8M
$12.4M
Q2 25
$176.9M
$11.6M
Q1 25
$124.3M
$-18.4M
Q4 24
$136.4M
$23.7M
Q3 24
$201.9M
$11.7M
Q2 24
$146.4M
$9.0M
Q1 24
$109.7M
$-18.6M
Free Cash Flow
IDA
IDA
OFIX
OFIX
Q4 25
$-216.2M
$16.8M
Q3 25
$-127.9M
$2.5M
Q2 25
$-156.4M
$4.5M
Q1 25
$-77.0M
$-25.1M
Q4 24
$-48.9M
$15.2M
Q3 24
$-16.1M
$6.3M
Q2 24
$-199.6M
$-360.0K
Q1 24
$-150.3M
$-29.1M
FCF Margin
IDA
IDA
OFIX
OFIX
Q4 25
-60.0%
7.6%
Q3 25
-24.3%
1.2%
Q2 25
-34.8%
2.2%
Q1 25
-18.7%
-13.0%
Q4 24
-13.0%
7.0%
Q3 24
-3.0%
3.2%
Q2 24
-45.1%
-0.2%
Q1 24
-36.0%
-15.4%
Capex Intensity
IDA
IDA
OFIX
OFIX
Q4 25
98.3%
4.9%
Q3 25
55.2%
4.8%
Q2 25
74.2%
3.5%
Q1 25
49.0%
3.5%
Q4 24
49.3%
4.0%
Q3 24
41.0%
2.7%
Q2 24
78.2%
4.7%
Q1 24
62.2%
5.6%
Cash Conversion
IDA
IDA
OFIX
OFIX
Q4 25
3.16×
Q3 25
1.31×
Q2 25
1.85×
Q1 25
2.08×
Q4 24
3.60×
Q3 24
1.78×
Q2 24
1.63×
Q1 24
2.28×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

IDA
IDA

Retailrevenues$323.0M90%
Transmissionserviceswheeling$18.6M5%
Energyefficiencyprogramrevenues$11.7M3%
Wholesaleenergysales$10.5M3%
Otherrevenues$9.5M3%

OFIX
OFIX

Spinal Implants Biologics And Enabling Technologies$113.6M52%
Bone Growth Therapies$68.3M31%
Other$22.7M10%
IT$5.9M3%
GB$3.5M2%
FR$3.5M2%
DE$2.3M1%

Related Comparisons